Aligos Therapeutics, Inc. (ALGS)

0,8101 -0,0359 (-4,24%) Alla chiusura: 04:00PM EDT

Aligos Therapeutics, Inc.

One Corporate Drive
2nd Floor
South San Francisco, CA 94080
United States
800 466 6059
https://www.aligos.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 66

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Lawrence M. Blatt MBA, Ph.D.	CEO, President & Chairman of the Board	1,03M	N/D	1962
Dr. Julian A. Symons DPHIL	Executive VP & Chief Scientific Officer	735,51k	N/D	1962
Dr. Matthew W. McClure M.D.	Executive VP & Chief Medical Officer	740,39k	N/D	1972
Kristina Engeseth	VP and Head of People & Culture	N/D	N/D	N/D
Dr. Sushmita M. Chanda DABT, Ph.D.	Executive Vice President & Chief Development Officer	N/D	N/D	1967
Dr. David B. Smith Ph.D.	Executive VP & Head of Chemical Operations	N/D	N/D	N/D
Dr. Tse-I Lin Ph.D.	VP of Early Compound Development & Belgian Site Head	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Aligos Therapeutics, Inc. al 1 maggio 2024 è 9. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.